CTLA4 and neoplasm: Agents such as QL1706 [106], MEDI5752 [107], and cadonilimab [108] are designed to simultaneously target PD-1 and CTLA-4 in a tumor-selective manner or optimized molecular formats, potentially reducing systemic toxicity without compromising efficacy.